PARP Inhibitor Advanced Breast Cancer Trials
PARP Inhibitor Trials for People with Advanced Breast Cancer
The below studies are PARP inhibitor studies that are currently enrolling patients with metastatic or locally advanced breast cancer. For more details on an individual study, please contact the study coordinator or visit clinicaltrials.gov.
- NCT01482715: A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast Cancer or Other Solid Tumor
- NCT01237067: Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers
- NCT00647062: AZD2281 and Carboplatin in Treating Patients With BRCA1/BRCA2-Associated, Hereditary, or Triple Negative Metastatic or Unresectable Breast Cancer or Ovarian Epithelial Cancer
- NCT01445418: AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
- NCT01173497: A Study Evaluating Iniparib in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
- NCT01306032: ABT-888 (veliparib)With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-NegativeBreast Cancer, and Low-Grade Non-Hodgkin's Lymphoma
- NCT01104259: Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer
- NCT01149083: Veliparib With or Without Carboplatin in Treating Patients With Stage III or Stage IV Breast Cancer
- NCT01251874: Veliparib and Carboplatin in Treating Women With HER2-Negative Metastatic Breast Cancer
- NCT00892736: ABT-888 in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
- NCT01281150: Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
- NCT01286987: Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Page updated 08/31/11
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.